United Therapeutics Beheer
Beheer criteriumcontroles 2/4
De CEO United Therapeutics is Martine Rothblatt, benoemd in Jan1996, heeft een ambtstermijn van 28.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 16.96M, bestaande uit 8.7% salaris en 91.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.44% van de aandelen van het bedrijf, ter waarde $ 241.05M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 15.6 jaar en 22.2 jaar.
Belangrijke informatie
Martine Rothblatt
Algemeen directeur
US$17.0m
Totale compensatie
| Percentage CEO-salaris | 8.7% |
| Dienstverband CEO | 28.8yrs |
| Eigendom CEO | 1.4% |
| Management gemiddelde ambtstermijn | 15.6yrs |
| Gemiddelde ambtstermijn bestuur | 22.2yrs |
Recente managementupdates
Recent updates
Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 18
Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price
Sep 27United Therapeutics: Economics Support Compounding Ability
Aug 20With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jul 26United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Jul 04United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market
Jun 13United Therapeutics: Exciting Company With A Big Problem
Jun 02We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease
Apr 05United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects
Mar 20Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings
Jan 02United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
Dec 08Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Nov 16United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Sep 04Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Aug 07United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
May 22Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?
Apr 25We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease
Feb 06With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jan 16Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 20United Therapeutics: Ability To Expand Tyvaso To Large IPF Market
Aug 24Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?
Aug 04United Therapeutics Q2 2022 Earnings Preview
Aug 02Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$1b |
| Jun 30 2024 | n/a | n/a | US$1b |
| Mar 31 2024 | n/a | n/a | US$1b |
| Dec 31 2023 | US$17m | US$1m | US$985m |
| Sep 30 2023 | n/a | n/a | US$900m |
| Jun 30 2023 | n/a | n/a | US$872m |
| Mar 31 2023 | n/a | n/a | US$728m |
| Dec 31 2022 | US$5m | US$1m | US$727m |
| Sep 30 2022 | n/a | n/a | US$707m |
| Jun 30 2022 | n/a | n/a | US$631m |
| Mar 31 2022 | n/a | n/a | US$687m |
| Dec 31 2021 | US$4m | US$1m | US$476m |
| Sep 30 2021 | n/a | n/a | US$462m |
| Jun 30 2021 | n/a | n/a | US$471m |
| Mar 31 2021 | n/a | n/a | US$405m |
| Dec 31 2020 | US$5m | US$1m | US$515m |
| Sep 30 2020 | n/a | n/a | US$469m |
| Jun 30 2020 | n/a | n/a | US$430m |
| Mar 31 2020 | n/a | n/a | US$528m |
| Dec 31 2019 | US$46m | US$1m | -US$104m |
| Sep 30 2019 | n/a | n/a | -US$92m |
| Jun 30 2019 | n/a | n/a | -US$118m |
| Mar 31 2019 | n/a | n/a | -US$150m |
| Dec 31 2018 | US$16m | US$1m | US$589m |
| Sep 30 2018 | n/a | n/a | US$543m |
| Jun 30 2018 | n/a | n/a | US$713m |
| Mar 31 2018 | n/a | n/a | US$484m |
| Dec 31 2017 | US$37m | US$1m | US$418m |
Compensatie versus markt: De totale vergoeding ($USD 16.96M ) Martine } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.87M ).
Compensatie versus inkomsten: De vergoeding van Martine is het afgelopen jaar met meer dan 20% gestegen.
CEO
Martine Rothblatt (69 yo)
28.8yrs
Tenure
US$16,958,057
Compensatie
Dr. Martine A. Rothblatt, Ph D., J.D., M.B.A., founded United Therapeutics Corporation in 1996 and has been its Chief Executive Officer since June 26, 2016 and as its Chairman since 1996. Dr. Rothblatt ser...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 28.8yrs | US$16.96m | 1.44% $ 241.1m | |
| President & COO | 8.4yrs | US$9.81m | 0.0058% $ 963.5k | |
| CFO & Treasurer | 11.8yrs | US$6.05m | 0.017% $ 2.8m | |
| Executive VP | 28.8yrs | US$5.15m | 0.082% $ 13.7m | |
| Head of Investor Relations | no data | geen gegevens | geen gegevens | |
| Associate Vice President of Human Resources | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Strategic Operations & Logistics | no data | geen gegevens | geen gegevens | |
| Executive VP of Technical Operations | 15.6yrs | geen gegevens | geen gegevens | |
| Executive Vice President of Product Development & Xenotransplantation | no data | geen gegevens | geen gegevens | |
| Senior VP & Chief Medical Officer | no data | geen gegevens | geen gegevens |
15.6yrs
Gemiddelde duur
56yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van UTHR is doorgewinterd en ervaren (gemiddelde ambtstermijn van 15.6 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 28.8yrs | US$16.96m | 1.44% $ 241.1m | |
| Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 22.8yrs | US$457.60k | 0.027% $ 4.5m | |
| Independent Director & Member of the Scientific Advisory Board | 22.2yrs | US$471.54k | 0.029% $ 4.9m | |
| Independent Director & Member of the Scientific Advisory Board | 22.8yrs | US$456.54k | 0.0039% $ 654.6k | |
| Independent Vice Chairman & Lead Independent Director | 22.1yrs | US$532.60k | 0.0045% $ 748.1k | |
| Independent Director | 21.3yrs | US$481.54k | 0.0094% $ 1.6m | |
| Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 22.8yrs | US$456.54k | 0.050% $ 8.4m | |
| Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 9.4yrs | US$488.66k | 0.017% $ 2.8m | |
| Independent Director | 15.6yrs | US$513.66k | 0.039% $ 6.5m |
22.2yrs
Gemiddelde duur
76yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van UTHR zijn ervaren en ervaren (gemiddelde ambtstermijn van 22.2 jaar).